Dimension Capital II, L.P.
Known title: DirectorCIK: 0002040933
Dimension Capital II, L.P.'s purchase track record
Dimension Capital II, L.P. has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/8/2026 | ODTX | $20.00M | +28.9% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ODTX | ▲ Buy | Open Market | 1,111,111 | $20.0M | 5/8/2026 | View on chart |
| ODTX | ▼ Sell | Other | 1,709,543 | — | 5/8/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Odyssey Therapeutics to Present OD-001 Data at UEG Week 2026
Odyssey Therapeutics announced that it will present additional Phase 2a induction data for its drug OD-001 in ulcerative colitis at the UEG Week 2026 conference. This upcoming presentation provides new clinical information on the company's lead candidate. The stock is currently trading near its 52-week low, with an average analyst target price of $35.75.
Odyssey Therapeutics to Present OD-001 Data at UEG Week 2026. Odyssey Therapeutics announced that it will present additional Phase 2a induction data for its drug OD-001 in ulcerative colitis at the UEG Week 2026 conference. This upcoming presentation provides new clinical information on the company's lead candidate. The stock is currently trading near its 52-week low, with an average analyst target price of $35.75.